Baker Bros. Advisors’s Protara Therapeutics TARA Stock Holding History

Baker Bros. Advisors’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.06M	Hold	971,614	–	–	0.03%	75
2025 Q4	$5.18M	Buy	971,614 +434,782	+81%	+$2.42M	0.03%	74
2025 Q3	$2.34M	Hold	536,832	–	–	0.02%	81
2025 Q2	$1.63M	Hold	536,832	–	–	0.02%	78
2025 Q1	$2.29M	Hold	536,832	–	–	0.03%	73
2024 Q4	$2.83M	Hold	536,832	–	–	0.03%	80
2024 Q3	$982K	Hold	536,832	–	–	0.01%	86
2024 Q2	$1.12M	Buy	536,832 +337,161	+169%	+$986K	0.01%	85
2024 Q1	$801K	Hold	199,671	–	–	0.01%	80
2023 Q4	$374K	Hold	199,671	–	–	﹤0.01%	79
2023 Q3	$333K	Hold	199,671	–	–	﹤0.01%	99
2023 Q2	$477K	Hold	199,671	–	–	﹤0.01%	103
2023 Q1	$625K	Hold	199,671	–	–	﹤0.01%	100
2022 Q4	$535K	Hold	199,671	–	–	﹤0.01%	103
2022 Q3	$591K	Hold	199,671	–	–	﹤0.01%	104
2022 Q2	$585K	Hold	199,671	–	–	﹤0.01%	108
2022 Q1	$1.02M	Hold	199,671	–	–	0.01%	107
2021 Q4	$1.35M	Hold	199,671	–	–	0.01%	113
2021 Q3	$1.38M	Hold	199,671	–	–	0.01%	114
2021 Q2	$1.95M	Hold	199,671	–	–	0.01%	111
2021 Q1	$3.14M	Hold	199,671	–	–	0.01%	107
2020 Q4	$4.83M	Hold	199,671	–	–	0.02%	92
2020 Q3	$3.36M	Hold	199,671	–	–	0.01%	90
2020 Q2	$5.85M	Hold	199,671	–	–	0.03%	76
2020 Q1	$4.59M	Buy	+199,671	New	+$5.82M	0.03%	66
2019 Q1	–	Sell	-7,465	Closed	-$678K	–	99
2018 Q4	$678K	Hold	7,465	–	–	0.01%	87
2018 Q3	$582K	Hold	7,465	–	–	﹤0.01%	95
2018 Q2	$732K	Hold	7,465	–	–	0.01%	110
2018 Q1	$746K	Hold	7,465	–	–	0.01%	105
2017 Q4	$567K	Hold	7,465	–	–	﹤0.01%	114
2017 Q3	$597K	Hold	7,465	–	–	﹤0.01%	113
2017 Q2	$455K	Hold	7,465	–	–	﹤0.01%	114
2017 Q1	$523K	Sell	7,465 -2,270	-23%	-$170K	﹤0.01%	111
2016 Q4	$740K	Buy	9,735 +2,270	+30%	+$718K	0.01%	116
2016 Q3	$2.79M	Hold	7,465	–	–	0.03%	83
2016 Q2	$2.4M	Hold	7,465	–	–	0.03%	92
2016 Q1	$2.31M	Hold	7,465	–	–	0.02%	97
2015 Q4	$4.63M	Buy	7,465 +600	+9%	+$352K	0.04%	79
2015 Q3	$3.82M	Buy	6,865 +2,446	+55%	+$1.51M	0.04%	84
2015 Q2	$3.16M	Buy	4,419 +96	+2%	+$59.4K	0.03%	91
2015 Q1	$2.01M	Hold	4,323	–	–	0.02%	106
2014 Q4	$1.8M	Buy	+4,323	New	+$1.74M	0.02%	102

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Baker Bros. Advisors's TARA Position: Q1 2026 in Review

Baker Bros. Advisors held its Protara Therapeutics (TARA) position steady in Q1 2026 at 971,614 shares worth $5.06M. The position accounts for 0.03% of the portfolio, ranked #75.

Baker Bros. Advisors first reported a position in TARA in Q4 2014 and has held it in 42 quarters since. The position peaked at $5.85M in Q2 2020. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

Baker Bros. Advisors held 971,614 shares of Protara Therapeutics worth $5.06M as of Q1 2026.
Baker Bros. Advisors left its Protara Therapeutics share count unchanged in Q1 2026.
Protara Therapeutics made up 0.03% of Baker Bros. Advisors's portfolio in Q1 2026, its #75 holding.
Baker Bros. Advisors first reported a position in Protara Therapeutics in Q4 2014 and has held it in 42 quarters since.
Baker Bros. Advisors's Protara Therapeutics position peaked at $5.85M in Q2 2020.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.